IONS Key Statistics, Chart & Performance
The current stock price of IONS is 83.07 USD. In the past month the price increased by 4.27%. In the past year, price increased by 164.55%.
IONS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IONS. When comparing the yearly performance of all stocks, IONS is one of the better performing stocks in the market, outperforming 96.53% of all stocks.
IONS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IONS. IONS has a bad profitability rating. Also its financial health evaluation is rather negative.
IONS Financial Highlights
Over the last trailing twelve months IONS reported a non-GAAP Earnings per Share(EPS) of -1.69. The EPS increased by 30.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.45% | ||
| ROE | -41.48% | ||
| Debt/Equity | 0.96 |
IONS Forecast & Estimates
29 analysts have analysed IONS and the average price target is 89.78 USD. This implies a price increase of 8.08% is expected in the next year compared to the current price of 83.07.
For the next year, analysts expect an EPS growth of 23.78% and a revenue growth 45.04% for IONS
IONS Ownership
IONS Latest News, Press Relases and Analysis
IONS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.88 | 398.79B | ||
| AMGN | AMGEN INC | 15.76 | 185.60B | ||
| GILD | GILEAD SCIENCES INC | 17.45 | 177.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.19 | 119.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.01 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 664.92 | 44.80B | ||
| INSM | INSMED INC | N/A | 32.84B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.7 | 26.27B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.45B | ||
| INCY | INCYTE CORP | 15.99 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.45B |
Related stock screener links
About IONS
Company Profile
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,069 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Company Info
IONIS PHARMACEUTICALS INC
2855 Gazelle Court
Carlsbad CALIFORNIA 92010 US
CEO: Brett P. MONIA
Employees: 1069
Phone: 17609319200
IONIS PHARMACEUTICALS INC / IONS FAQ
What does IONS do?
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,069 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
What is the stock price of IONIS PHARMACEUTICALS INC today?
The current stock price of IONS is 83.07 USD. The price increased by 0.48% in the last trading session.
Does IONS stock pay dividends?
IONS does not pay a dividend.
How is the ChartMill rating for IONIS PHARMACEUTICALS INC?
IONS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is IONIS PHARMACEUTICALS INC (IONS) stock traded?
IONS stock is listed on the Nasdaq exchange.
What is the expected growth for IONS stock?
The Revenue of IONIS PHARMACEUTICALS INC (IONS) is expected to grow by 45.04% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.